Rational Design of Hybrid Peptides: A Novel Drug Design Approach

Abstract

Peptides play crucial roles in various physiological and pathological processes. Consequently, the investigation of peptide-based drugs is a highlight in the research and development of new drugs. However, natural peptides are not always ideal choices for clinical application due to their limited number and sometimes cytotoxicity to normal cells. Aiming to gain stronger or specific or novel biological effects and overcome the disadvantages of natural peptides, artificial hybrid peptides have been designed by combining the sequence of two or more different peptides with varied biological functions. Compared to natural peptides, hybrid peptides have shown better therapeutic potentials against bacteria, tumors, and metabolic diseases. In this review, design strategies, structure features and recent development of hybrid peptides are summarized; future directions for the research and development of hybrid peptide drugs are also discussed.

Keywords

hybrid peptides / design strategies / antibacterial / anti-tumor and anti-metabolic diseases / chemical modification

References

[1] MaL, YangC, ZhangX, et al.. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson’s disease. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(12): 3714-3725

[2] ZhangY, GuoX, YanW, et al.. ANGPTL8 negatively regulates NF-κB activation by facilitating selective autophagic degradation of IKKγ. Nat Commun, 2017, 8(1): 2164

[3] TangML, BaiXJ, LiY, et al.. MMP-1 Over-expression Promotes Malignancy and Stem-Like Properties of Human Osteosarcoma MG-63 Cells In Vitro. Curr Med Sci, 2018, 38(5): 809-817

[4] BuchwaldH, DormanRB, RasmusNF, et al.. Effects on GLP-1, PYY, and leptin by direct stimulation of terminal ileum and cecum in humans: implications for ileal transposition. Surg Obes Relat Dis, 2014, 10(5): 780-786

[5] GiordanoC, MarchiòM, TimofeevaE, et al.. Neuroactive peptides as putative mediators of antiepileptic ketogenic diets. Front Neurol, 2014, 5: 63

[6] KeldF, TorstenH. Peptide therapeutics: current status and future directions. Drug Discov Today, 2015, 20(1): 122-128

[7] ChenH, WanD, WangL, et al.. Apelin protects against acute renal injury by inhibiting TGF-β1. Biochim Biophys Acta Mol Basis Dis, 2015, 1852(7): 1278-1287

[8] ChenH, LiJ, JiaoL, et al.. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. J Physiol, 2014, 592(3): 505-521

[9] MignognaG, SeveriniC, ErspamerGF, et al.. Tachykinins and other biologically active peptides from the skin of the Costa Rican phyllomedusid frog Agalychnis callidryas. Peptides, 1997, 18(3): 367-372

[10] ChenH, WangL, WangW, et al.. ELABELA and an ELABELA Fragment Protect against AKI. J Am Soc Nephrol, 2017, 28(9): 2694-2707

[11] HayashiK, HamadaY, ShioiriT. Synthesis of nazumamide A, a thrombin-inhibitory linear tetrapeptide, from a marine sponge, Theonella sp. Tetrahedron Lett, 1992, 33(35): 5075-5076

[12] ChenH, LiuC, ChengC, et al.. Effects of apelin peptides on diabetic complications. Curr Protein Pept Sci, 2018, 19(2): 179-189

[13] DuVV, ResslerC, TrippettS. The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin. J Biol Chem, 1953, 205(2): 949-957

[14] D’HondtM, BrackeN, TaevernierL, et al.. Related impurities in peptide medicines. J Pharm Biomed Anal, 2014, 101: 2-30

[15] YeamanMR, YountNY. Mechanisms of Antimicrobial Peptide Action and Resistance. Pharmacol Rev, 2003, 55(1): 27-55

[16] MaL, WangC, HeZ, et al.. Peptide-Drug Conjugate: A Novel Drug Design Approach. Curr Med Chem, 2017, 24(31): 3373-3396

[17] PapoN, ShaiY. New Lytic Peptides Based on the D, L-Amphipathic Helix Motif Preferentially Kill Tumor Cells Compared to Normal Cells. Biochemistry, 2003, 42(31): 9346-9354

[18] KawamotoM, KohnoM, HoribeT, et al.. Immunogenicity and toxicity of transferrin receptor-targeted hybrid peptide as a potent anticancer agent. Cancer Chemother Pharmacol, 2013, 71(3): 799-807

[19] HasibA, NgMT, KhanD, et al.. A novel GLP-1/ xenin hybrid peptide improves glucose homeostasis, circulating lipids and restores GIP sensitivity in high fat fed mice. Peptides, 2018, 100: 202-211

[20] HjorthSA, AdelhorstK, PedersenBB, et al.. Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J Biol Chem, 1994, 269(48): 30121-30124

[21] RungeS, GramC, BraunerosborneH, et al.. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem, 2003, 278(30): 28005-28010

[22] DayJW, OttawayN, PattersonJT, et al.. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol, 2009, 5(10): 749-757

[23] EckertR, QiFD, HeJ, et al.. Adding Selectivity to Antimicrobial Peptides: Rational Design of a Multidomain Peptide against Pseudomonas spp. Antimicrob Agents Chemother, 2006, 50(4): 1480-1488

[24] HeJ, AndersonMH, ShiW, et al.. Design and activity of a ‘dual-targeted’ antimicrobial peptide. Int J Antimicrob Agents, 2009, 33(6): 532-537

[25] FinanB, YangB, OttawayN, et al.. Targeted estrogen delivery reverses the metabolic syndrome. Nat Med, 2012, 18(12): 1847-1856

[26] FinanB, ClemmensenC, ZhuZ, et al.. Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease. Cell, 2016, 167(3): 843-857

[27] ComegnaD, ZannettiA, Dei GattoA, et al.. Chemical Modification for Proteolytic Stabilization of the Selective αvβ3 Integrin RGDechi Peptide: In Vitro and In Vivo Activities on Malignant Melanoma Cells. J Med Chem, 2017, 60(23): 9874-9884

[28] ReddyKV, YederyRD, AranhaC. Antimicrobial peptides: premises and promises. Int J Antimicrob Agents, 2004, 24(6): 536-547

[29] HancockRE, ScottMG. The Role of Antimicrobial Peptides in Animal Defenses. Proc Nati Acad Sci USA, 2000, 97(16): 8856-8861

[30] KangSJ, ParkSJ, Mishig-OchirT, et al.. Antimicrobial peptides: therapeutic potentials. Expert Rev Anti Infect Ther, 2014, 12(12): 1477-1486

[31] EckertR, HeJ, YarbroughDK, et al.. Targeted Killing of Streptococcus mutans by a Pheromone-Guided “Smart” Antimicrobial Peptide. Antimicrob Agents Chemother, 2006, 50(11): 3651-3657

[32] WeiX, WuR, ZhangL, et al.. Expression, Purification, and Characterization of a Novel Hybrid Peptide with Potent Antibacterial Activity. Molecules, 2018, 23: 1491-1502

[33] NasongklaN, ShuaiX, AiH, et al.. cRGD-functionalized polymer micelles for targeted doxorubicin delivery. Angew Chem Int Ed Engl, 2004, 43(46): 6323-6327

[34] RadyI, SiddiquiI A, RadyM, et al.. Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett, 2017, 402: 16-31

[35] LiX, TaratulaO, TaratulaO, et al.. LHRH-Targeted Drug Delivery Systems for Cancer Therapy. Mini Rev Med Chem, 2017, 17(3): 258-267

[36] YangD, ZouR, ZhuY, et al.. Magainin II modified polydiacetylene micelles for cancer therapy. Nanoscale, 2014, 6(24): 14772-14783

[37] HoribeT, KohnoM, HaramotoM, et al.. Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent. J Transl Med, 2011, 9: 8

[38] YangL, HoribeT, KohnoM, et al.. Targeting interleukin-4 receptor α with hybrid peptide for effective cancer therapy. Mol Cancer Ther, 2012, 11(1): 235-243

[39] TadaN, HoribeT, HaramotoM, et al.. A single replacement of histidine to arginine in EGFR-lytic hybrid peptide demonstrates the improved anticancer activity. Biochem Biophys Res Commun, 2011, 407(2): 383-388

[40] HuangW, LuL, ShaoX, et al.. Anti-melanoma activity of hybrid peptide P18 and its mechanism of action. Biotechnol Lett, 2010, 32(4): 463-469

[41] HabeggerKM, HeppnerKM, AmburgySE, et al.. GLP- 1R Responsiveness Predicts Individual Gastric Bypass Efficacy on Glucose Tolerance in Rats. Diabetes, 2014, 63(2): 505-513

[42] SalehiM, D’AlessioDA. Effects of glucagon like peptide-1 to mediate glycemic effects of weight loss surgery. Rev Endocr Metab Disord, 2014, 15(3): 171-179

[43] ZhouB, JiK, PengA, et al.. GLP-1(28-36)amide, a Long Ignored Peptide Revisited. Open Biochem J, 2014, 8(1): 107-111

[44] VilsbøllT, ChristensenM, JunkerAE, et al.. Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 2012, 344: d7771

[45] DavidsonIW, SalterJM, BestCH. Calorigenic action of glucagon. Nature, 1957, 180(4595): 1124

[46] JoelCD. Stimulation of metabolism of rat brown adipose tissue by addition of lipolytic hormones in vitro. J Biol Chem, 1966, 241(4): 814-821

[47] KuroshimaA, YahataT. Thermogenic responses of brown adipocytes to noradrenaline and glucagon in heat-acclimated and cold-acclimated rats. Jpn J Physiol, 1979, 29(6): 683-690

[48] MüllerWA, FaloonaGR, Aguilar-ParadaE, et al.. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med, 1970, 283(3): 109-115

[49] DayJW, OttawayN, PattersonJT, et al.. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol, 2009, 5(10): 749-757

[50] ClemmensenC, ChabenneJ, FinanB, et al.. GLP-1/Glucagon Coagonism Restores Leptin Responsiveness in Obese Mice Chronically Maintained on an Obesogenic Diet. Diabetes, 2014, 63(4): 1422-1427

[51] DayJW, GelfanovV, SmileyD, et al.. Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents. Biopolymers, 2012, 98(5): 443-450

[52] FinanB, MaT, OttawayN, et al.. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med, 2013, 5(209): 209ra151

[53] FinanB, YangB, OttawayN, et al.. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med, 2015, 21(1): 27-36

[54] TschöpM, FinanB, ClemmensenC, et al.. Unimolecular Polypharmacy for Treatment of Diabetes and Obesity. Cell Metab, 2016, 24(1): 51-62

[55] HasibA, NgMT, KhanD, et al.. Characterisation and antidiabetic utility of a novel hybrid peptide, exendin-4/gastrin/xenin-8-Gln. Eur J Pharmacol, 2018, 834: 126-135

[56] ShinA, LeeE, JeonD, et al.. Peptoid-Substituted Hybrid Antimicrobial Peptide Derived from Papiliocin and Magainin 2 with Enhanced Bacterial Selectivity and Anti-inflammatory Activity. Biochemistry, 2015, 54(25): 3921-3931

[57] LiuY, XiaX, XuL, et al.. Design of hybrid β-hairpin peptides with enhanced cell specificity and potent anti-inflammatory activity. Biomaterials, 2013, 34(1): 237

[58] KaczyńskaK, KogutE, ZającD, et al.. Neurotensin-based hybrid peptide’s anti-inflammatory activity in murine model of a contact sensitivity response. Eur J Pharm Sci, 2016, 93: 84-89

[59] PaulA, NadimpallyKC, MondalT, et al.. Inhibition of Alzheimer’s amyloid-β peptide aggregation and its disruption by a conformationally restricted α/β hybrid peptide. Chem Commun, 2015, 51(12): 2245-2248

[60] KumarS, PaulA, KalitaS, et al.. Protective effects of β-sheet breaker α/β-hybrid peptide against amyloid β- induced neuronal apoptosis in vitro. Chem Biol Drug Des, 2017, 89(6): 888-900

[61] ChengB, GongH, XiaoH, et al.. Inhibiting toxic aggregation of amyloidogenic proteins: A therapeutic strategy for protein misfolding diseases. Biochim Biophys Acta, 2013, 1830(10): 4860-4871

[62] MaL, ZhaoY, ChenY, et al.. Caenorhabditis elegans, as a model system for target identification and drug screening against neurodegenerative diseases. Eur J Pharmacol, 2018, 819: 169-180

[63] ChengB, GongH, LiX, et al.. Salvianolic acid B inhibits the amyloid formation of human islet amyloid polypeptideand protects pancreatic beta-cells against cytotoxicity. Proteins, 2013, 81(4): 613-621

[64] ChengB, GongH, LiX, et al.. Silibinin inhibits the toxic aggregation of human islet amyloid polypeptide. Biochem Biophys Res Commun, 2012, 419(3): 495-499

[65] ChengB, LiuX, GongH, et al.. Coffee Components Inhibit Amyloid Formation of Human Islet Amyloid Polypeptide in Vitro: Possible Link between Coffee Consumption and Diabetes Mellitus. J Agric Food Chem, 2011, 59(24): 13147-13155

[66] GongH, HeZ, PengA, et al.. Effects of several quinones on insulin aggregation. Sci Rep, 2014, 4: 5648

[67] ChenY, XuX, HongS, et al.. RGD-Tachyplesin inhibits tumor growth. Cancer Res, 2001, 61(6): 2434-2438

[68] EllerbyHM, ArapW, EllerbyLM, et al.. Anti-cancer activity of targeted pro-apoptotic peptides. Nat Med, 1999, 5(9): 1032-1038

[69] DelongT, WilesTA, BakerRL, et al.. Pathogenic CD4 T cells in type 1 diabetes recognize epitopes formed by peptide fusion. Science, 2016, 351(6274): 711-714

[70] DongG L, ParkY, JinI, et al.. Structure-antiviral activity relationships of cecropin A-magainin 2 hybrid peptide and its analogues. J Pept Sci, 2004, 10(5): 298